Medicomp, Inc. Announces New Mobile Cardiac Telemetry System for Cardiac Patients

   Medicomp Inc., a leading cardiac telemedicine provider and wholly-owned subsidiary of United Therapeutics Corporation, announced that it received FDA clearance for its new SAVI Wireless Mobile Cardiac Telemetry (MCT) system.    The new device will initially be used for the identification of symptomatic and asymptomatic cardiac arrhythmias. SAVI Wireless builds on Medicomp’s foundation of over 28 years of diagnostic, ambulatory electrocardiogram (ECG) expertise.    SAVI Wireless brings Medicomp’s proprietary ECG algorithm, Diogenes, into the wireless world. Diogenes is the only ECG algorithm FDA cleared to analyze rate, rhythm, morphology, and p-wave abnormalities. The sophistication of the on-board algorithm and its ability to automatically capture arrhythmias the patient does not feel makes the SAVI Wireless a new option in Mobile Cardiac Telemetry.    Paul H. Nguyen, MD, MS of Elite Cardiology Solutions, commented, “The patient convenience of the new SAVI Wireless combined with Medicomp’s proven algorithm will transform the way physicians diagnose cardiac arrhythmias and this will translate to better patient outcomes.”    SAVI Wireless systems are provided to patients who are suspected of having infrequent cardiac arrhythmia. The proprietary monitoring system collects, analyzes, and wirelessly sends clinically relevant symptomatic and asymptomatic arrhythmia data to Medicomp's 24/7/365 Cardiac Monitoring Center over the cellular network. Certified cardiac technicians then review the data and prepare customized reports for the treating physician. The system has bi-directional communication and the ability to save and retrieve up to 30 days of 2-channel ECG.     “Medicomp’s new SAVI Wireless is the only Mobile Cardiac Telemetry system FDA cleared to analyze the p-wave, making it the right choice for monitoring patients suspected of having atrial fibrillation and other complex arrhythmias,” said Dan Balda, MD, President of Medicomp. “The new system was designed to be versatile enough to ultimately receive data from a variety of sources that will be monitoring several disease states in a single patient, and collate the various bio- markers along a common time axis.”